Document Type : Original Article
Authors
1
Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2
Faculty of Advanced Sciences and technology, Tehran Medical Sciences,Islamic azad university: Tehran, Tehran, IRAN
3
Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
4
Resalat Highway, Ostad-Hassan Street. City: Tehran. Postal code: 1663684313 Iran- Phone No: +989141637563
10.22074/cellj.2024.2022401.1506
Abstract
Objective: The objective of this study was to assess whether Spen paralogue and orthologue C-terminal domain containing 1 (SPOCD1) gene expression could serve as a valuable prognostic and diagnostic biomarker in common cancers, drawing from insights in recent literature. We sought to verify this concept by utilizing data sourced from The Cancer Genome Atlas (TCGA) alongside clinical samples.
Materials and methods: In this bioinformatics and experimental study, SPOCD1 RNA-seq data from 12 common cancers were collected from TCGA Pan-Cancer Atlas using the R package "TCGA BIOLINKS" and normalized for analysis. Various analytical tools were applied, including ROC curves, Kaplan-Meier and Cox-regression analyses, and pathway enrichment analysis using the molecular signatures database (MSigDB). Drug resistance/sensitivity correlations with SPOCD1 expression were explored using the Gene Expression Omnibus (GEO) database. Clinical colorectal cancer (CRC) samples consisting both colon and rectal malignant samples. were also included in the evaluation.
Results: The results revealed elevated SPOCD1 expression in most cancers (9/12), with notable prognostic value in COAD, HNSC, KICH, and LIHC, as well as a correlation with poor prognosis in COAD for disease-free survival. ROC curve analysis suggested SPOCD1 as a diagnostic biomarker in the majority of cases (7/12), although this pattern was not consistent in clinical CRC samples. Pathway enrichment analysis supported a strong correlation between SPOCD1 expression and critical molecular pathways. Furthermore, anticancer drug testing showed that SPOCD1 overexpression correlated with sensitivity to PD-0325901 but resistance to Lapatinib and Panobinostat.
Conclusion: The present study confirmed highlighted function and underscores the potential of SPOCD1 as a significant diagnostic and prognostic biomarker across prevalent cancers, supported by robust data and analysis the functions and effects of SPOCD1 in the majority of prevalent cancers. Sufficient and appropriate data have been presented, leading to the conclusion that SPOCD1 merits consideration as a significant diagnostic and prognostic candidate for the cancers examined herein.
Keywords
Main Subjects
', './data/cellj/coversheet/cover_en.jpg'))